| Drug Name: | Indinavir (150378-17-9) |
|---|---|
| PubChem ID: | 5362440 |
| SMILES: | CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5 |
| InchiKey: | CBVCZFGXHXORBI-PXQQMZJSSA-N |
| Therapeutic Category: | Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiviral Agents, Enzyme Inhibitors, HIV Protease Inhibitors, Protease Inhibitors |
| Molecular Weight (dalton) | : | 613.803 |
| LogP | : | 2.8669 |
| Ring Count | : | 3 |
| Hydrogen Bond Acceptor Count | : | 7 |
| Hydrogen Bond Donor Count | : | 4 |
| Total Polar Surface Area | : | 118.03 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Ergotamine (113-15-5) | Ergotism | Synergistic | Protease inhibitors reduce the metabolism of ergotamine by inhibiting the cytochrome P450 isoenzyme CYP3A4 to varying degrees. Therefore ergotamine levels are increased, which | Ergotism related to concurrent administration of ergotamine tartrate and indinavir |
| Levodopa (59-92-7) | Dyskinesia | Synergistic | Uncertain | Protease inhibitors enhance levodopa effects in Parkinson's disease |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Hyperlipidemia | Adiponectin (Q15848) | Dose-responsive inhibition of adipogenesis by indinavir was noted as measured by reduced triglyceride accumulation and attenuated induction of three differentiation marker genes -- aP2@ lipoprotein lipase@ and Adipo Q@which leads to a syndrome characterized by lipodystrophy (fat redistribution favoring the accumulation of abdominal and cervical adipose tissue)@ hyperlipidemia@ and insulin resistance. [ ADR Type 1 ] | Inhibition of adipocyte differentiation by HIV protease inhibitors |
| Hyperlipidemia | Lipoprotein lipase precursor (P06858) | Dose-responsive inhibition of adipogenesis by indinavir was noted as measured by reduced triglyceride accumulation and attenuated induction of three differentiation marker genes -- aP2@ lipoprotein lipase@ and Adipo Q@which leads to a syndrome characterized by lipodystrophy (fat redistribution favoring the accumulation of abdominal and cervical adipose tissue)@ hyperlipidemia@ and insulin resistance [ ADR Type 1 ] | Inhibition of adipocyte differentiation by HIV protease inhibitors |
| Hyperlipidemia | Transcription factor AP-2 alpha;AP-2 complex subunit alpha-2;AP-2 complex subunit beta-1 (P05549) | Dose-responsive inhibition of adipogenesis by indinavir was noted as measured by reduced triglyceride accumulation and attenuated induction of three differentiation marker genes -- aP2@ lipoprotein lipase@ and Adipo Q@which leads to a syndrome characterized by lipodystrophy (fat redistribution favoring the accumulation of abdominal and cervical adipose tissue)@ hyperlipidemia@ and insulin resistance. [ ADR Type 1 ] | Inhibition of adipocyte differentiation by HIV protease inhibitors |
| Increasing Adverse Effects | Cytochrome P450 3A4 (P08684) | Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4 Coadministration of CRIXIVAN and drugs primarily metabolized by CYP3A4 may result in increased plasma concentrations of the other drug@ which could increase or prolong its therapeutic and adverse effects [ ADR Type 4 ] | Use of terfenadine and contraindicated drugs |
| Insulin Resistance | Adiponectin (Q15848) | Dose-responsive inhibition of adipogenesis by indinavir was noted as measured by reduced triglyceride accumulation and attenuated induction of three differentiation marker genes -- aP2@ lipoprotein lipase@ and Adipo Q@which leads to a syndrome characterized by lipodystrophy (fat redistribution favoring the accumulation of abdominal and cervical adipose tissue)@ hyperlipidemia@ and insulin resistance. [ ADR Type 1 ] | Inhibition of adipocyte differentiation by HIV protease inhibitors |
| Insulin Resistance | Lipoprotein lipase precursor (P06858) | Dose-responsive inhibition of adipogenesis by indinavir was noted as measured by reduced triglyceride accumulation and attenuated induction of three differentiation marker genes -- aP2@ lipoprotein lipase@ and Adipo Q@which leads to a syndrome characterized by lipodystrophy (fat redistribution favoring the accumulation of abdominal and cervical adipose tissue)@ hyperlipidemia@ and insulin resistance [ ADR Type 1 ] | Inhibition of adipocyte differentiation by HIV protease inhibitors |
| Insulin Resistance | Transcription factor AP-2 alpha;AP-2 complex subunit alpha-2;AP-2 complex subunit beta-1 (P05549) | Dose-responsive inhibition of adipogenesis by indinavir was noted as measured by reduced triglyceride accumulation and attenuated induction of three differentiation marker genes -- aP2@ lipoprotein lipase@ and Adipo Q@which leads to a syndrome characterized by lipodystrophy (fat redistribution favoring the accumulation of abdominal and cervical adipose tissue)@ hyperlipidemia@ and insulin resistance. [ ADR Type 1 ] | Inhibition of adipocyte differentiation by HIV protease inhibitors |
| Lipodystrophy | Adiponectin (Q15848) | Dose-responsive inhibition of adipogenesis by indinavir was noted as measured by reduced triglyceride accumulation and attenuated induction of three differentiation marker genes -- aP2@ lipoprotein lipase@ and Adipo Q@which leads to a syndrome characterized by lipodystrophy (fat redistribution favoring the accumulation of abdominal and cervical adipose tissue)@ hyperlipidemia@ and insulin resistance. [ ADR Type 1 ] | Inhibition of adipocyte differentiation by HIV protease inhibitors |
| Lipodystrophy | Lipoprotein lipase precursor (P06858) | Dose-responsive inhibition of adipogenesis by indinavir was noted as measured by reduced triglyceride accumulation and attenuated induction of three differentiation marker genes -- aP2@ lipoprotein lipase@ and Adipo Q@which leads to a syndrome characterized by lipodystrophy (fat redistribution favoring the accumulation of abdominal and cervical adipose tissue)@ hyperlipidemia@ and insulin resistance [ ADR Type 1 ] | Inhibition of adipocyte differentiation by HIV protease inhibitors |
| Lipodystrophy | Transcription factor AP-2 alpha;AP-2 complex subunit alpha-2;AP-2 complex subunit beta-1 (P05549) | Dose-responsive inhibition of adipogenesis by indinavir was noted as measured by reduced triglyceride accumulation and attenuated induction of three differentiation marker genes -- aP2@ lipoprotein lipase@ and Adipo Q@which leads to a syndrome characterized by lipodystrophy (fat redistribution favoring the accumulation of abdominal and cervical adipose tissue)@ hyperlipidemia@ and insulin resistance. [ ADR Type 1 ] | Inhibition of adipocyte differentiation by HIV protease inhibitors |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|---|---|
| Garlic | Reduce Bioavailability | http://ummedu/health/medical/altmed/herb-interaction/possible-interactions-with-garlic |
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category